-
Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.
Oncoscience | November 6th, 2020
Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...
-
Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab
Oncoscience | March 25th, 2019
The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffe...
-
Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland
Oncoscience | October 3rd, 2018
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...
-
Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
Oncoscience | November 17th, 2017
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab...
-
legal form changed
Oncoscience | August 22nd, 2017
We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....
